Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 24;13(3):219-236.
doi: 10.5306/wjco.v13.i3.219.

Immunotherapy in triple-negative breast cancer: A literature review and new advances

Guillermo Arturo Valencia  1 , Patricia Rioja  2 , Zaida Morante  2 , Rossana Ruiz  2 , Hugo Fuentes  2 , Carlos A Castaneda  2 , Tatiana Vidaurre  2 , Silvia Neciosup  2 , Henry L Gomez  2
Affiliations
Review

Immunotherapy in triple-negative breast cancer: A literature review and new advances

Guillermo Arturo Valencia et al. World J Clin Oncol. .

Abstract

Triple-negative breast cancer (TNBC) is a highly complex, heterogeneous disease and historically has limited treatment options. It has a high probability of disease recurrence and rapid disease progression despite adequate systemic treatment. Immunotherapy has emerged as an important alternative in the management of this malignancy, showing an impact on progression-free survival and overall survival in selected populations. In this review we focused on immunotherapy and its current relevance in the management of TNBC, including various scenarios (metastatic and early -neoadjuvant, adjuvant-), new advances in this subtype and the research of potential predictive biomarkers of response to treatment.

Keywords: Biomarkers; Early disease; Immunotherapy; Metastatic disease; Triple-negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: None to declare.

References

    1. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288–300. - PubMed
    1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. - PubMed
    1. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5:412–424. - PMC - PubMed
    1. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–2767. - PMC - PubMed
    1. Franzoi MA, Romano E, Piccart M. Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol. 2021;32:323–336. - PubMed